BriaCell Therapeutics (BCTX) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed Rein Therapeutics (RNTX) over the past year, losing 61.7% versus a loss of 77.2%. Over five years, BCTX leads with a -97.0% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $26.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | RNTX |
|---|---|---|
| Share price | $3.06 | $0.3369 |
| Market cap | $26.72M | $29.06M |
| 1-day change | -3.32% | -8.38% |
| YTD return | -56.96% | -70.96% |
| 1-year return | -61.75% | -77.24% |
| 5-year return | -97.00% | -97.47% |
| EPS (TTM) | $-6.97 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-34.90M | $-49.87M |
| 52-week high | $13.09 | $2.10 |
| 52-week low | $2.60 | $0.284 |
| Distance from 52-week high | -76.62% | -83.96% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1680.94% |
| Average volume | 250.81K | 586.68K |
| Shares outstanding | 8.73M | 86.27M |
| Employees | — | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCTX has outperformed RNTX by 15.5 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
BCTX vs RNTX FAQ
Which is bigger, BriaCell Therapeutics or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $26.72M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or RNTX?
BCTX returned -61.75% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.